84691-16-7

Usage

Properties

1. Chemical compound: 3-Isoxazolecarboxylic acid, 4-hydroxy-, ethyl ester (9CI)
2. Classification: Isoxazolecarboxylic acid derivative
3. Structure: Ethyl ester of 4-hydroxy-3-isoxazolecarboxylic acid

Specific content

1. Potential intermediate: It is a potential intermediate in the synthesis of various pharmaceutical compounds.
2. Medicinal chemistry: It may have potential applications in the field of medicinal chemistry.
3. Drug development: It may have potential uses in drug development.
4. Structural properties: Its structure provides unique properties and functional groups.
5. Further research: More research is required to fully understand its chemical and biological properties.
6. Pharmaceutical industry: It may have potential uses in the pharmaceutical industry.

Upstream product

• 638-07-3 ethyl (2-chloroaceto)acetate 
• 110-46-3 isopentyl nitrite 
• 66340-85-0 ethyl 4-bromo-2-hydroxyimino-3-oxobutyrate 
• 50382-11-1 ethyl γ-chloro-α-oximinoacetoacetate 
• 75689-07-5 ethyl 4-bromo-2-(hydroxyimino)-3-oxobutanoate 
• 13176-46-0 4-bromoethyl acetoacetate 
• 141-97-9 ethyl acetoacetate 

Relevant academic research and scientific papers

GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula II.

GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I), as follows: wherein R1, R2, R4, W, X, Y, and G, are defined herein.

GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (III); wherein R1c, R2C, R4C, Wc, Yc, Zc and Gc, are defined herein.

HETEROCYCLIC SUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND THEIR USE

The present application relates to novel heterocyclically substituted 6-(trifluoromethyl)pyrimidin-4(3H)-one derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular, renal, inflammatory and fibrotic diseases.

HETEROCYCLICALLY SUBSTITUTED TRIFLUOROMETHYLPYRIMIDINONES AND THEIR USE

The present application relates to novel heterocyclically substituted 6-(trifluoromethyl)pyrimidin-4(3H)-one derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular, renal, inflammatory and fibrotic diseases.

Anti-ulcer pyridyloxy derivatives, their preparation and uses

Compounds of formula (I): STR1 [wherein: R1 is a cyclic amino group, or a dialkylamino group; R2 a group of formula --NHCHR3 R4 wherein R3 and R4 are each alkyl aryl or aralkyl, or together form a cycloalkyl group, or R2 is an aromatic heterocyclic group, or a group of formula --B--S(O)m --R5 wherein R5 is a substituted alkyl group, or an aromatic heterocyclic group; B is an alkylene or alkylidene group; m is 0, 1 or 2; A is a group of formula --CH=CH-- or --(CH2)n --, where n is 1, 2 or 3]; and salts thereof have valuable anti-ulcer activity.